Congenital heart diseases involving congenitally diseased pulmonary valve phenotypes: Novel insights into the health care burden across the life course Authors: Chantal M Sanchez, Sarah Crook, Pengfei Jiang, Kacie Dragan, Joyce L Woo, Jane W Newburger, Marshall L Jacobs, Andrew B Goldstone, Katherine Nash, Robert Vincent, Kathleen Walsh-Spoonhower, Ralph Mosca, Susheel Kumar, Neil Devejian, Ben Biddix, George M Alfieris, Michael F Swartz, David Meyer, John Billings, Brett R Anderson Published: 2026 ABSTRACT AbstractObjectivesWe characterize comprehensive health care use and Medicaid expenditures for all patients in New York State (NYS) enrolled in Medicaid (2007-2019) with congenitally diseased pulmonary valve phenotypes across the life course.MethodsWe leverage The Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources linked clinical registry, National Death Index, and NYS Medicaid claims data and describe Medicaid expenditures and health care use across the life course for all patients with congenitally diseased pulmonary valves enrolled in Medicaid who underwent cardiac surgery. Outcomes are compared with noncardiac, Medicaid-enrolled, comparators.ResultsAmong 1068 unique patients from NYS enrolled in Medicaid (7594 patient-years), the average patient with congenital pulmonary valve diseases was estimated to spend 851 days (∼2.3 years) touching the health care system before age 65 years, totaling ∼$2.9 M in Medicaid expenditures—6 times greater than that observed among noncardiac comparators. Inpatient, emergency department, sick primary care, and subspecialist visits and total Medicaid expenditures all peaked in infancy ($353 K per person-year; 95% CI, $316-390 K), nadired in childhood ($25 K per person-year; 95% CI, $23-26 K), and increased again in adulthood ($43 K per person-year; 95% CI, $42-54 K).ConclusionsChildren with congenitally diseased pulmonary valve phenotypes who are enrolled in Medicaid experience high health care use and health-related expenditures that persist across the life course and increase sharply in early and middle adulthood. These findings underscore the need for improved care coordination, novel disease-specific interventions, and policies to reduce long-term burden for this population.Key Words: health care use, pulmonary valve disease, disease burden, congenital heart disease Congenitally diseased PV phenotypes: Medicaid expenditures across the life course. Central Message Children with primary, congenitally diseased pulmonary valve phenotypes incur high health care use and costs (∼$2.9 M across the lifetime), underscoring the need for lifelong, coordinated care. Perspective Children with congenitally diseased pulmonary valve phenotypes face sustained health care needs despite improved survival. Using linked clinical registry, Medicaid claims, and mortality data, we found persistently high health care burden across the life course. These findings underscore the need for improved care coordination, disease-specific interventions, and policies to reduce long-term burden. Although acute mortality associated with congenital heart defects has improved in recent decades, the longitudinal health care burden for survivors remains high.1 Therapeutic advances are needed to reduce disease burden across the life course, yet comprehensive, long-term, disease-specific data are limited. In previous work, The Congenital Heart Surgery-COllaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR) has used linked cardiac surgical registry, Medicaid claims, and the National Death Index to describe long-term health care use and Medicaid expenditures for cardiac surgical patients across New York State (NYS), yet stratified analyses to date have been limited to broad cardiac disease severity categories, the presence or absence of preoperative comorbidities, and basic patient demographics. Phenotype-specific data are needed to guide therapeutic advances. Congenital heart diseases involving primary, congenital defects of the pulmonary valve (PV) are among the most common forms of congenital heart disease, with an estimated incidence of clinically significant disease requiring intervention of 1.5 to 2.5 per 1000 live births.2,3 These conditions are clinically heterogeneous, ranging from isolated valvar stenosis to tetralogy of Fallot (TOF), TOF with absent PV, and even pulmonary atresia (PA).4,5 Yet all of these patients require at least 1—and often multiple—interventions on their PVs, options for which remain limited, and often inadequate, for small children.3,6,7 Using congenital PV disease as a test case, we sought to demonstrate that population-level, clinical registry data linked to Medicaid claims and the National Death Index could be used to characterize comprehensive, longitudinal, baseline global disease burden for specific congenital heart disease populations. Methods Data Source We conducted a longitudinal cohort study using linked, prospectively collected CHS-COLOUR NYS data. The CHS-COLOUR collaborative previously linked 20 years of locally held Society of Thoracic Surgeons Congenital Heart Surgery Database (STS-CHSD) and NYS Pediatric Congenital Cardiac Surgery clinical registry data from 10 of 11 pediatric cardiac surgical centers across NYS (1999-2019) to NYS Medicaid claims (2006-2019) and the National Death Index using direct patient identifiers.8 The STS-CHSD captures >90% of all US congenital heart surgeries (100% in NYS), with 10% of participating centers audited annually.9,10 The NYS Pediatric Congenital Cardiac Surgery clinical registry is a mandatory NYS Department of Health pediatric cardiac surgical registry.11 These registries include >200 clinically specific diagnostic and >200 clinically specific procedure codes, defined by the cardiac surgical community and manually abstracted from medical records by cardiac surgical teams for public reporting—not billing—purposes, increasing specificity over International Classification of Diseases codes.12,13 Greater than one half (53%) of patients from NYS who underwent congenital heart surgical during our study window were receiving NYS Medicaid.8 Case Definition Before cohort identification, “clinically significant, primary congenital pulmonary valve disease” needed to first be clearly defined. To ensure that we considered all clinical phenotypes at risk for interventions on the PV, the clinical registry was first queried for all patients who ever underwent a pulmonary valvuloplasty or replacement. Frequency tables were constructed for all STS-CHSD patient diagnoses, subdiagnoses, and procedures and were manually reviewed by a pediatric cardiologist (B.A.). Patients fell into the following phenotype categories: (1) TOF with pulmonary stenosis (PS), including ventricular septal defect with PS (VSD-PS); (2) TOF with PA (TOF-PA), including VSD with PA (VSD-PA); (3) atrioventricular septal defect with TOF with complete atrioventricular canal (AVSD-TOF); (4) TOF with absent PV (TOF absent PV); (5) valvar PS without VSD (valvar PS no VSD); (6) primary left-sided cardiac disease with secondary PV disease (eg, aortic stenosis requiring Ross or Ross-Konno); (7) dextro-transposition of the great arteries; (8) Ebstein anomaly; (9) other. “Other” represented a small number of patients who appeared to have primary PV disease but whose combination of subdiagnoses and subprocedure codes was either rare or left ambiguity regarding the specific phenotype. The category “other” included, for example, patients with a diagnosis of PV stenosis who undergo right ventricle-to-pulmonary artery conduit as their first and only intervention in the registry. Groupings were reviewed by all coauthors; a clinical decision was made to exclude primary left-sided lesions, dextro-transposition of the great arteries, and Ebstein anomaly, resulting in a final total of 6 diagnostic categories: (1) TOF-PS or VSD-PS; (2) TOF-PA or VSD-PA; (3) AVSD-TOF; (4) TOF absent PV; (5) valvar PS no VSD; (6) other. Study Population CHS-COLOUR data were queried for all patients with primary, congenitally diseased PV phenotypes, as defined previously, who underwent at least 1 congenital heart surgery (1999-2019). The cohort was restricted to patients who enrolled in NYS Medicaid for at least 10 continuous months (2006-2019). Patients who disenrolled and re-enrolled in Medicaid were allowed to contribute data from multiple enrollment periods, provided re-enrollment lasted at least 10 months. Noncardiac Comparators To provide context for our results, a comparison cohort of NYS Medicaid-enrolled children who never underwent cardiac surgery was identified. Comparators were included if they were continuously enrolled for at least 10 months. Because both children with cardiac disease and the broader pediatric population can have other, noncardiac conditions, and because the population incidence and severity of many of these conditions is modified by the presence of congenital heart disease, we do not match on nor exclude patients with noncardiac comorbidities. Therefore, the comparison cohort is representative of all other children on NYS Medicaid, not specifically children with no health conditions. Outcomes The primary outcomes were the number and duration of inpatient admissions, the number of emergency department visits, primary care sick visits, outpatient subspecialist visits, and ambulatory procedure visits, total Medicaid expenditures per patient-year, and Medicaid expenditures per patient-year attributable to hospitalizations or ambulatory visits in which cardiac surgeries or cardiac catheterizations were performed. Total days in health care was also calculated as the sum of inpatient, emergency department, and outpatient days. Total Medicaid expenditures included all dollars paid by Medicaid for services including—but not limited to—inpatient, outpatient, emergency, pharmacy, rehabilitation, home health, and educational services. Expenditures were adjusted to 2024 US dollars, using the Medical Consumer Price Index.14 Visit types were defined in accordance with The Centers for Medicaid & Medicare Services and the NYS Department of Health's Type of Service Classifications. We use the phrase “ambulatory procedure visits” to refer to ambulatory surgical services, because this category includes surgical and catheterization procedures performed in ambulatory surgical or hospital-based centers for which the expected length of stay is <24 hours (42 Code of Federal Regulations 416; 10 New York Codes, Rules and Regulations 755). Statistical Analyses Patient demographics, clinical characteristics, and unadjusted outcomes are described using standard summary statistics for patients with congenital PV phenotypes and noncardiac comparators. To account for dynamic Medicaid enrollment and disenrollment, all outcomes were characterized per person-year within prespecified age groups: <1 year, 1 to 4 years, 5 to 12 years, 13 to 21 years, 22 to 44 years, and 45 to 65 years. For individuals who died during the observation period and were enrolled for fewer than 10 months, expenditures were prorated to reflect a full year of on the basis of the proportion of months observed. Poisson models that allowed for overdispersion characterized adjusted, predicted mean use per-patient within age group and log-linear models characterized adjusted, predicted mean expenditures and total days in health care. All models were adjusted for sex, race/ethnicity, preoperative comorbidity (noncardiac congenital anatomic abnormality, chromosomal abnormality, or syndrome),8 other preoperative risk factors (preoperative mechanical circulatory support, shock persistent at time of surgery, preoperative mechanical ventilation, renal failure requiring dialysis, neurologic deficit, or other preoperative factor),8 and PV phenotype. Predicted values from log-linear models were exponentiated and adjusted using the Duan smearing estimator to correct for retransformation bias. Values reflect the average, adjusted, annual rates or geometric mean and 95% CIs. Total days in health care and total expenditures per patient (birth to age 65 years) were estimated as the sum of predicted mean expenditures per patient-year within age group. Average annual costs to the NYS Medicaid program associated with the care of all patients enrolled in Medicaid with clinically significant, primary, congenitally diseased PV phenotypes were estimated. Cells with <13 patients were suppressed in accordance with NYS Medicaid standards to prevent patient reidentification. Analyses were performed in Stata, version 14.2 (StataCorp). Western Institutional Review Board approved this study, and a waiver of consent was obtained (no.: 20200200). Results We identified a total of 1068 unique patients from NYS enrolled in Medicaid with primary, congenitally diseased PV phenotypes (contributing a total of 7594 Medicaid-enrolled person-years). Patients were born 1949 to 2019, with a median birth year in 2006 (interquartile range [IQR], 2000-2012). Table 1 describes overall cohort demographic and clinical characteristics. The median, cumulative duration of NYS Medicaid enrollment during the 14-year study window was 5.6 years (IQR, 2.5-10.3 years). The majority of patients (77%, n = 778) had TOF-PS or VSD-PS. Eight percent (n = 86) had TOF-PA or VSD-PA (8%); 7% (n = 75) had AVSD-TOF; less than 3% (n < 31) had TOF with absent PV; 5% (n = 54) had valvar PS no VSD; and 4% (n = 44) were characterized as other. Table 1Demographics and clinical characteristics of patients with congenitally diseased pulmonary valve phenotypes who ever underwent cardiac surgery in New York State (1997 to 2019) and who were ever enrolled in New York Medicaid (2006 to 2019)Demographics and clinical characteristicsCardiac enrollees (n = 1068)Non-cardiac enrollees (n = 10,321,792)Age at initial cardiac surgery (year of birth) <1 y (1990-2019)721 (68%)N/A 1-4 y (1988-2018)103 (10%)N/A 5-12 y (1983-2013)59 (6%)N/A 13-21 y (1976-2006)89 (8%)N/A 22-44 y (1965-1996)<70 (<6%)∗N/A >45 y (1949-1974)<31 (<3%)∗N/ASex Female484 (45%)5,440,088 (53%) Male583 (55%)4,880,747 (47%)Race/ethnicity Hispanic323 (30%)1,505,590 (15%) Non-Hispanic Black252 (24%)1,873,340 (18%) Non-Hispanic White277 (26%)3,101,689 (30%) Non-Hispanic Asian138 (13%)1,000,147 (10%) Other78 (7%)2,841,026 (28%)Noncardiac congenital anomaly, syndrome, or genetic anomaly317 (30%)N/APrematurity (n = 423)88 (21%)N/AOther preoperative risk factors226 (21%)N/APulmonary valve phenotype TOF-PS, including VSD-PS778 (77%)N/A TOF-PA, including VSD-PA86 (8%)N/A AVSD-TOF75 (7%)N/A TOF Absent PV<31 (<3%)∗N/A Valvar PS no VSD54 (5%)∗N/A Other<54 (<5%)∗N/ADuration of Medicaid enrollment, y Mean (SD)6.6 y (4.4)5.2 y (4.0) Median (IQR)5.6 y (2.5–10.3)4.0 y (1.8-8.0)Data are presented as unadjusted means with SDs, medians with interquartile ranges (IQRs), or numbers (n) and percents. NA, Not available; TOF-PS, including VSD-PS, tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the STS-CHSD data left ambiguity regarding the specific, underlying clinical diagnosis.∗Values suppressed because of small sample size. Demographics and clinical characteristics of patients with congenitally diseased pulmonary valve phenotypes who ever underwent cardiac surgery in New York State (1997 to 2019) and who were ever enrolled in New York Medicaid (2006 to 2019) Data are presented as unadjusted means with SDs, medians with interquartile ranges (IQRs), or numbers (n) and percents. NA, Not available; TOF-PS, including VSD-PS, tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the STS-CHSD data left ambiguity regarding the specific, underlying clinical diagnosis. Values suppressed because of small sample size. Health Care Use by Age Group Health care use across the life course for patients with congenitally diseased PV phenotypes and noncardiac comparators is summarized in Table 2 by health care encounter type. Table 3 describes the contributions of hospital admissions and ambulatory visits in which cardiac surgeries or cardiac catheterizations were performed. Table 4 compares total days in health care by PV disease phenotype across the life course. Table E1, Table E2, Table E3, Table E4, Table E5 detail health care use by encounter type, stratified by PV disease phenotype. Table 2Health care use for patients with congenitally diseased pulmonary valve (PV) phenotypes versus noncardiac comparators (NC) across the life courseAge at observation on New York Medicaid(person-years under observation) [birth years]<1 year old(PV: 695 p-yr)(NC: 1.8 M p-yr)[2005-2019]1-4 years old(PV: 2222 p-yr)(NC: 5.5 M p-yr)[2001-2018]5-12 year old(PV: 2609 p-yr)(NC: 9.3 M p-yr)[1978-2014]13-21 year old(PV: 1240 p-yr)(NC: 8.9 M p-yr)[1978-2006]22-44 year old(PV: 720 p-yr)(NC: 16.7 M p-yr)[1964-1997]45-65 year old(PV: 108 p-yr)(NC: 12.4 M p-yr)[1949-1976]PV: inpatient days, per p-yr Mean (SD)42.6 (61.8)4.1 (21.3)1.0 (4.9)1.4 (6.0)3.4 (13.3)6.1 (20.5) Median (IQR)19.0 (11.0-43.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-2.0) Adjusted, predicted mean (95% CI)38.7 (35.1-42.2)3.8 (3.0-4.7)0.8 (0.6-1.0)1.5 (1.1-1.8)3.9 (1.7-5.1)7.0 (2.5-11.4) Patients with ≥1 inpatient stay, n (%)667 (96%)518 (23%)250 (10%)190 (15%)167 (23%)(∼25%)∗Noncardiac: inpatient days, per p-yr Mean (SD)5.2 (12.2)0.2 (3.2)0.2 (4.5)0.7 (8.1)1.4 (8.7)2.0 (12.0) Median (IQR)3.0 (3.0-4.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-2.0) Patients with ≥1 inpatient stay, n (%)1,568,777 (87%)205,223 (4%)189,904 (2%)512,792 (6%)2,121,595 (13%)1,611,923 (13%)Pulmonary valve: ED visits, per p-yr Mean (SD)0.9 (1.4)0.7 (1.4)0.3 (0.9)0.3 (0.9)0.5 (1.8)0.4 (1.1) Median (IQR)0.0 (0.0-1.0)0.0 (0.0-1.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0- 0.0)0.0 (0.0-0.0) Adjusted, predicted mean (95% CI)0.9 (0.0-2.3)0.6 (0.0-1.7)0.3 (0.0-0.9)0.3 (0.0-0.9)0.5 (0.0-1.3)0.4 (0.0-1.0) Patients with ≥1 ED visit, n (%)315 (45%)743 (33%)569 (22%)249 (20%)167 (23%)(∼15%)∗ Patients with ≥2 ED visits, n (%)153 (22%)349 (16%)190 (7%)96 (7%)78 (10%)(∼10%)∗Noncardiac: ED visits, per p-yr Mean (SD)0.7 (1.3)0.5 (1.1)0.3 (0.7)0.3 (1.0)0.5 (1.6)0.4 (1.8) Median (IQR)0.0 (0.0-1.0)0.0 (0.0-1.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0) Patients with ≥1 ED visit, n (%)608,018 (34%)1,566,317 (18%)1,655,501 (18%)1,617,529 (18%)3,725,688 (13%)2,334,358 (19%)Pulmonary valve: PCP sick visits, per p-yr Mean (SD)13.1 (10.1)6.7 (8.9)3.7 (4.7)2.6 (3.4)3.0 (4.4)3.8 (4.0) Median (IQR)11.0 (6.0-17.0)4.5 (2.0-9.0)2.0 (1.0-5.0)1.3 (0.0-4.0)1.3 (0.0-4.0)3.0 (1.0-6.0) Adjusted, predicted mean (95% CI)12.8 (12.1-13.6)6.6 (6.3-7.0)3.7 (3.5-3.9)2.6 (2.4-2.8)3.0 (2.7-3.3)3.8 (3.1-4.6) Patients with ≥2 PCP visits, n (%)638 (92%)1720 (77%)1608 (62%)601 (48%)357 (49%)(∼65%)∗ Patients with ≥5 PCP visits, n (%)583 (84%)1113 (50%)740 (28%)224 (18%)162 (22%)(∼33%)∗Noncardiac valve: PCP sick visits, per p-yr Mean (SD)3.4 (4.7)2.8 (4.1)1.8 (3.0)1.3 (2.5)1.8 (3.3)3.1 (4.7) Median (IQR)2.0 (0.0-6.0)2.0 (0.0-4.0)1.0 (0.0-3.0)0.0 (0.0-2.0)1.0 (0.0-2.0)2.0 (0.0-4.0) Patients with ≥2 PCP visits, n (%)1,056,214 (59%)2,744,152 (50%)3,472,930 (37%)2,460,836 (28%)5,826,391 (35%)6,253,494 (50%) Patients with ≥5 PCP visits, n (%)582,184 (32%)1,209,894 (22%)1,101,025 (12%)671,039 (7%)2,146,426 (13%)2,984,726 (24%)Pulmonary valve: outpatient subspecialist visits, per p-yr Mean (SD)7.0 (6.1)2.6 (3.7)1.7 (2.7)1.8 (3.5)2.8 (3.6)5.0 (6.8) Median (IQR)6.0 (2.0-10.0)1.0 (0.0-3.0)1.0 (0.0-2.0)1.0 (0.0-2.0)2.0 (0.0-4.0)3.5 (1.0-6.0) Adjusted, predicted mean (95% CI)6.8 (6.3-7.2)2.6 (2.4-2.7)1.7 (1.6-1.8)1.8 (1.6-2.0)2.9 (2.6-3.2)4.8 (3.6-6.1) Patients with ≥1 subspecialist visit, n (%)596 (86%)1533 (69%)1544 (59%)732 (59%)491 (68%)(∼80%)∗Noncardiac: outpatient subspecialist visits, per p-yr Mean (SD)0.9 (2.1)0.6 (1.6)0.5 (1.5)0.9 (1.9)1.7 (3.4)2.4 (4.8) Median (IQR)0.0 (0.0-1.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-1.0)0.7 (0.0-2.0)1.0 (0.0-3.0) Patients with ≥1 subspecialist visit, n (%)559,585 (31%)1,331,260 (24%)2,063,290 (22%)2,564,139 (29%)7,808,416 (47%)6,596,027 (53%)Pulmonary valve: ambulatory procedure visits, per p-yr Mean (SD)1.1 (2.3)0.6 (1.8)0.4 (1.5)0.4 (1.7)0.8 (5.1)0.5 (1.6) Median (IQR)0.0 (0.0-1.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0) Adjusted, predicted mean (95% CI)1.1 (0.9-1.2)0.5 (0.5-0.6)0.4 (0.3-0.4)0.4 (0.3-0.5)0.8 (0.5-1.1)0.5 (0.2-0.8) Patients with ≥1 visit, n (%)264 (38%)483 (22%)420 (16%)204 (16%)121 (17%)(∼20%)∗Noncardiac: ambulatory procedure visits, per p-yr Mean (SD)0.2 (1.0)0.1 (0.8)0.2 (1.4)0.2 (1.4)0.2 (2.2)0.5 (4.3) Median (IQR)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0)0.0 (0.0-0.0) Patients with ≥1 visit, n (%)228,795 (13%)387,533 (7%)595,809 (6%)630,235 (7%)1,503,037 (9%)1,690,098 (13%)Pulmonary valve patient data were derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). Control data were derived from a total of 10,321,792 individuals over a total of 54,530,162 Medicaid-enrolled p-yr. Data are presented as unadjusted means with SDs, medians with interquartile ranges (IQRs), and numbers (n) and percent. Visit types are defined in accordance with The Centers for Medicaid & Medicare Services and the New York State Department of Health's Type of Service Classifications. We use the phrase “ambulatory procedure visits” to refer to ambulatory surgical services, as this category includes surgical and catheterization procedures performed in ambulatory surgical or hospital-based centers for which the expected length-of-stay is <24 h (42 CFR 416; 10 NYCRR 755). CFR: Code of Federal Regulations; ED, emergency department; NYCRR: New York Codes, Rules and Regulations; PCP, primary care practice.∗Values suppressed because of small sample size. Health care use for patients with congenitally diseased pulmonary valve (PV) phenotypes versus noncardiac comparators (NC) across the life course Pulmonary valve patient data were derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). Control data were derived from a total of 10,321,792 individuals over a total of 54,530,162 Medicaid-enrolled p-yr. Data are presented as unadjusted means with SDs, medians with interquartile ranges (IQRs), and numbers (n) and percent. Visit types are defined in accordance with The Centers for Medicaid & Medicare Services and the New York State Department of Health's Type of Service Classifications. We use the phrase “ambulatory procedure visits” to refer to ambulatory surgical services, as this category includes surgical and catheterization procedures performed in ambulatory surgical or hospital-based centers for which the expected length-of-stay is <24 h (42 CFR 416; 10 NYCRR 755). CFR: Code of Federal Regulations; ED, emergency department; NYCRR: New York Codes, Rules and Regulations; PCP, primary care practice. Values suppressed because of small sample size. Table 3Hospital admission or ambulatory visit involving cardiac surgery or cardiac catheterization and associated Medicaid expenditures (2024 US$) for patients with congenitally diseased pulmonary valve phenotypes across the life courseAge at observation on Medicaid(person-years under observation)Mean total cardiac procedure-related Medicaid expenditures across the life course<1 year old(695 p-yr)1-4 years old(2222 p-yr)5-12 y(2609 p-yr)13-21 y(1240 p-yr)22-44 y(720 p-yr)45-65 y(108 p-yr)Cardiac procedure incidence0.90 per p-yr(0.80-1.0)0.15 per p-yr(0.13-0.17)0.09 per p-yr(0.06-0.11)0.15 per p-yr(0.12-0.18)0.15 per p-yr(0.10-0.19)0.53 per p-yr(0.16-0.90)Mean Medicaid expenditures attributable to cardiac procedure-related encounters$114,289 per p-yr($97,343-$131,234)$69,947 per p-yr($54,356-$85,538)$74,150 per p-yr($51,744-$96,557)$74,305 per p-yr($54,535-$94,075)$57,789 per p-yr($34,203-$81,375)$77,008 per p-yr($30,448-$123,567)$0.5 M per person% Mean Medicaid expenditures attributable to cardiac procedure-related encounters10% per p-yr7% per p-yr5% per p-yr13% per p-yr5% per p-yr20% per p-yr11% per personData presented as adjusted, predicted means, and 95% CIs per person-year (p-yr), derived from a total of 1068 people over a total of 7594 Medicaid-enrolled person-years. Cardiac procedure associated Medicaid expenditures. Hospital admission or ambulatory visit involving cardiac surgery or cardiac catheterization and associated Medicaid expenditures (2024 US$) for patients with congenitally diseased pulmonary valve phenotypes across the life course Data presented as adjusted, predicted means, and 95% CIs per person-year (p-yr), derived from a total of 1068 people over a total of 7594 Medicaid-enrolled person-years. Cardiac procedure associated Medicaid expenditures. Table 4Total days in health care for patients with congenitally diseased pulmonary valve phenotypes, 2006-2019, stratified by cardiac diagnosisPulmonary valve phenotypeAge at observation on New York Medicaid (days per person-year, p-yr)(Person-years under observation)Total days in health care across the life course, per person<1 year old(695 p-yr)1-4 years old(2222 p-yr)5-12 y(2609 p-yr)13-21 y(1240 p-yr)22-44 y(720 p-yr)45-65 y(108 p-yr)TOF-PS, including VSD-PS68 d per p-yr(64-73)13 d per p-yr(13-14)8 d per p-yr(7-8)7 d per p-yr(7-7)10 d per p-yr(10-11)15 d per p-yr(12-18)797 d per personTOF-PA, including VSD-PA100 d per p-yr(89-110)19 d per p-yr(18-21)11 d per p-yr(10-12)10 d per p-yr(9-11)16 d per p-yr(14-18)1160 d per personAVSD-TOF76 d per p-yr(68-84)15 d per p-yr(13-16)8 d per p-yr(8-9)8 d per p-yr(7-8)12 d per p-yr(11-13)886 d per personTOF Absent PV96 d per p-yr(82-110)19 d per p-yr(16-21)11 d per p-yr(9-12)10 d per p-yr(8-11)15 d per p-yr(13-17)1118 d per personValvar PS no VSD64 d per p-yr(56-72)12 d per p-yr(11-14)7 d per p-yr(6-8)6 d per p-yr(6-7)10 d per p-yr(9-11)742 d per personOther87 d per p-yr(76-97)17 d per p-yr(15-19)10 d per p-yr(9-11)9 d per p-yr(8-10)14 d per p-yr(12-15)1009 d per personDays in health care reflect total days in hospital, emergency department, or outpatient visits. Use does not include isolated laboratory testing or radiology procedures. Data represent predicted means and 95% CIs, derived from log-linear models from a total of 1068 people (p) over a total of 7594 Medicaid-enrolled person-years (p-yr), adjusted for sex, race/ethnicity, preoperative comorbidity (non-cardiac congenital anatomic abnormality, chromosomal abnormality, or syndrome), other preoperative risk factors (preoperative mechanical circulatory support, shock persistent at time of surgery, preoperative mechanical ventilation, renal failure requiring dialysis, neurologic deficit, or other preoperative factor), and pulmonary valve phenotype, stratified by age category. TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Some values for adults presented as aggregated estimates due to small cell sizes. Total days in health care for patients with congenitally diseased pulmonary valve phenotypes, 2006-2019, stratified by cardiac diagnosis Days in health care reflect total days in hospital, emergency department, or outpatient visits. Use does not include isolated laboratory testing or radiology procedures. Data represent predicted means and 95% CIs, derived from log-linear models from a total of 1068 people (p) over a total of 7594 Medicaid-enrolled person-years (p-yr), adjusted for sex, race/ethnicity, preoperative comorbidity (non-cardiac congenital anatomic abnormality, chromosomal abnormality, or syndrome), other preoperative risk factors (preoperative mechanical circulatory support, shock persistent at time of surgery, preoperative mechanical ventilation, renal failure requiring dialysis, neurologic deficit, or other preoperative factor), and pulmonary valve phenotype, stratified by age category. TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Some values for adults presented as aggregated estimates due to small cell sizes. In risk-adjusted models, the projected mean patient with a congenitally diseased PV phenotype was estimated to spend 851 days (∼2.3 years) touching the health care system (in-hospitals, doctors’ offices, emergency departments, and outpatient procedures) before age 65 years. This included 73 days in the first year of life (95% CI, 68-78; 39 days in-hospitals, 95% CI, 35-42), 9 days per person-year across childhood and adolescence, and 11 days per person-year by early adulthood (22-44 years old, 95% CI 10-12 days). Correspondingly, the incidence of hospitalizations and ambulatory visits involving cardiac surgeries or cardiac catheterizations was greatest in infancy (0.90 per person-year; 95% CI, 0.80-1.0), decreased to less than 0.2 visits per person-year throughout childhood and early adulthood, and increased to 0.5 per person-year (95% CI, 0.16-0.90) by middle adulthood (45-65 years). Use was not limited to inpatient admissions or a select few patients. Almost one quarter of infants went to emergency departments 2 or more times (22%; n = 153); nearly one half went at least once (45%; n = 315 person-years). Sixteen percent of children per-year ages 1 to 4 years (n = 349 person-years), 7% of children per year ages 5 to 21 years (n = 284 person-years), and 10% of adults per year ages 22 to 65 years (n = 99 person-years) went to emergency departments 2 or more times. Primary care sick visits and outpatient subspecialist visits followed similar trends. Sixty percent of infants per year (n = 415 person-years) and 8% of adults per year ages 22-44 years went to ≥5 primary care sick visits per person-year; each year, 35 to 79% of observed patients attended at least 1 outpatient subspecialist appointment. Patients with TOF-PS and those with valvar PS with no VSD spent the fewest days in health care per person-year across all age cohorts, but these patients still averaged 68 and 76 (95% CIs 64-73 and 56-72) days per person in the first year of life, respectively, 8 days per person-year throughout childhood, and 10 days per-year by their early 20s. Patients with TOF-PA, TOF absent PV, and other spent the most days in health care per person-year across all age cohorts, totaling >1000 days by age 65 years. Predicted mean use followed a similar inverse parabolic pattern across age groups across all PV phenotypes, with the lowest mean use per patient-year consistently observed among patients classified as TOF-PS and valvar PS no VSD. Medicaid-enrolled noncardiac comparators displayed a similar pattern in health care use across time, but with lower total use (mean 387 days before age 65 years; median 107). In the first year of life, infants in the noncardiac group spent an average of 5.2 inpatient days per person-year (SD 12.2); median 3.0 (IQR 3.0-4.0). Inpatient use for noncardiac comparators nadired at an average of 0.2 days per person-year in early childhood (median, 0.0; IQR, 0.0-0.0), before increasing to 2.0 days per person-year in later adulthood (45-65 years of age; SD, 12.0; median, 0.0; IQR, 0.0-2.0). Annual Medicaid Expenditures Across the 14-year study window, the NYS Medicaid program spent an average of $35 M per year in the care of patients with primary congenital PV disease phenotypes. Medicaid expenditures across the life course are summarized in Figure 1, Table 3, and Table 5. Total mean predicted lifetime Medicaid expenditures for patients with primary congenital PV disease phenotypes was $2.9 M per person (birth to 65 years), with an estimated $0.5 M per person attributable directly to hospitalizations or ambulatory visits in which cardiac surgeries or cardiac catheterizations were performed. Expenditures were greatest in infancy (predicted mean $353 K per person-year, 95% CI, $316 K-$390 K), with 10% of expenditures per person-year attributable to cardiac procedural visits, lowest in school age children 5-21 years (predicted mean $25-28 K per person-year; 7% per person-year attributable to cardiac procedural visits), and high again in adulthood (45-65 years, predicted mean $43 K per person-year, 95% CI $32 K-$54 K; 20% per person-year attributable to cardiac procedural visits). This trend was similar across all phenotypes, with the greatest per person-year expenditures observed among patients with TOF-PA and AVSD-TOF across all age cohorts. Although the total predicted lifetime Medicaid expenditures were lowest among patients with TOF-PS (∼$2.5 M per person) and valvar PS no VSD (∼$2.3 M per person), the population associated with the greatest annual financial burden for the NYS Medicaid program was TOF-PS, given its high prevalence; NYS Medicaid spent ∼$25 M each year for patients with TOF-PS. Table 6 details predicted mean Medicaid expenditures per-patient year, stratified by PV disease phenotype. Congenitally diseased pulmonary valve phenotypes: Medicaid expenditures across the life course. Expenditures presented as geometric means in US 2024$ per person-year (p-yr), from birth through age 65 years. Total expenditures include all dollars paid by New York State Medicaid, including—but not limited to—inpatient, outpatient, emergency, pharmacy, rehabilitation, home health, and educational services. Table 5Medicaid expenditures (2024 US$) for patients with congenitally diseased pulmonary valve phenotypes versus noncardiac control patients across the life coursePatients with congenitally diseased pulmonary valve phenotypesAge at observation on Medicaid (person-years under observation)Mean total Medicaid expenditures across the life courseStatewide NYS Medicaid expenditures for patients with congenitally diseased pulmonary valve phenotypes<1 year old(695 p-yr)1-4 years old(2222 p-yr)5-12 y(2609 p-yr)13-21 y(1240 p-yr)22-44 y(720 p-yr)45-65 y(108 p-yr)Predicted mean(95% CI)$352,996 per p-yr($315,872-$390,120)$36,009 per p-yr($33,667-$38,350)$24,814 per p-yr($23,275-$26,353)$27,666 per p-yr($25,374-$29,957)$44,417 per p-yr($39,645-$49,189)$42,700 per p-yr($31,674-$53,726)$2.9 M per person$35 M per yearNoncardiac control patientsAge at observation on Medicaid(person-years under observation)Total Medicaid expenditures across the life course<1 year old(1,798,750 p-yr)1-4 years old(5,450,297 p-yr)5-12 year old(9,312,258 p-yr)13-21 y(8,869,005 p-yr)22-44 y(16,652,618 p-yr)45-65 y(12,447,234 p-yr) Mean (SD)$11,731 per p-yr($34,186)$2733 per p-yr($15,507)$2527 per p-yr($15,511)$4170 per p-yr($25,046)$8410 per p-yr($37,706)$13,889 per p-yr($43,110)$0.5 M per person Median (IQR)$7701 per p-yr($4775-$10,389)$790 per p-yr($346-$1734)$697 per p-yr($275-$1640)$781 per p-yr($230-$2229)$1875 per p-yr($424-$5552)$3287 per p-yr($808-$9606)Data for pulmonary valve patients are presented as predicted means and 95% CIs, derived from log-linear models from a total of 1068 people (p) over a total of 7594 Medicaid-enrolled person-years (p-yr), adjusted for sex, race/ethnicity, preoperative comorbidity (noncardiac congenital anatomic abnormality, chromosomal abnormality, or syndrome), other preoperative risk factors (preoperative mechanical circulatory support, shock persistent at time of surgery, preoperative mechanical ventilation, renal failure requiring dialysis, neurologic deficit, or other preoperative factor), and pulmonary valve phenotype, stratified by age category. Data for noncardiac control patients are presented as unadjusted means with SDs and medians with interquartile ranges (IQRs), derived from a total of 10,321,792 people over 54,530,162 Medicaid-enrolled p-yr. Medicaid expenditures (2024 US$) for patients with congenitally diseased pulmonary valve phenotypes versus noncardiac control patients across the life course Data for pulmonary valve patients are presented as predicted means and 95% CIs, derived from log-linear models from a total of 1068 people (p) over a total of 7594 Medicaid-enrolled person-years (p-yr), adjusted for sex, race/ethnicity, preoperative comorbidity (noncardiac congenital anatomic abnormality, chromosomal abnormality, or syndrome), other preoperative risk factors (preoperative mechanical circulatory support, shock persistent at time of surgery, preoperative mechanical ventilation, renal failure requiring dialysis, neurologic deficit, or other preoperative factor), and pulmonary valve phenotype, stratified by age category. Data for noncardiac control patients are presented as unadjusted means with SDs and medians with interquartile ranges (IQRs), derived from a total of 10,321,792 people over 54,530,162 Medicaid-enrolled p-yr. Table 6Medicaid expenditures (2024 US$) for patients with congenitally diseased pulmonary valve phenotypes, 2006-2019, stratified by cardiac diagnosisPulmonary valve phenotypeAge at observation on New York Medicaid(person-years under observation)Total mean Medicaid expenditures across the life course<1 year old(695 p-yr)1-4 years old(2222 p-yr)5-12 y(2609 p-yr)13-21 y(1240 p-yr)22-44 y(720 p-yr)45-65 y(108 p-yr)TOF-PS, including VSD-PS$307,375 per p-yr($274,594-$340,156)$31,355 per p-yr($29,240-$33,471)$21,607 per p-yr($20,200-$23,014)$24,090 per p-yr($22,004-$26,176)$38,676 per p-yr($34,398-$42,955)$37,182 per p-yr($27,540-$46,823)$2.5 M per personTOF-PA, including VSD-PA$492,854 per p-yr($418,279-$567,428)$50,276 per p-yr($43,857-$56,695)$34,645 per p-yr($30,176-$39,115)$38,627 per p-yr($33,289-$43,966)$61,688 per p-yr($52,247-$71,130)$4.0 M per personAVSD-TOF$485,673 per p-yr($411,263-$560,083)$49,543 per p-yr($43,203-$55,884)$34,141 per p-yr($29,905-$38,376)$38,064 per p-yr($32,957-$43,171)$60,803 per p-yr($51,738-$69,869)$4.0 M per personTOF Absent PV$459,347 per p-yr($365,720-$552,974)$46,858 per p-yr($38,139-$55,577)$32,290 per p-yr($26,368-$38,211)$36,001 per p-yr($29,092-$42,910)$57,535 per p-yr($45,831-$69,239)$3.8 M per personValvar PS no VSD$276,677 per p-yr($226,598-$326,756)$28,224 per p-yr($23,645-$32,802)$19,449 per p-yr($16,270-$22,628)$21,684 per p-yr($17,934-$25,434)$34,646 per p-yr($28,357-$40,935)$2.3 M per personOther$446,110 per p-yr($368,050-$524,170)$45,507 per p-yr($38,494-$52,520)$31,359 per p-yr($26,635-$36,083)$34,964 per p-yr($29,444-$40,483)$55,842 per p-yr($47,261-$64,422)$3.7 M per personData represent predicted means and 95% CIs, derived from log-linear models from a total of 1068 people (p) over a total of 7594 Medicaid-enrolled person-years (p-yr), adjusted for sex, race/ethnicity, preoperative comorbidity (noncardiac congenital anatomic abnormality, chromosomal abnormality, or syndrome), other preoperative risk factors (preoperative mechanical circulatory support, shock persistent at time of surgery, preoperative mechanical ventilation, renal failure requiring dialysis, neurologic deficit, or other preoperative factor), and pulmonary valve phenotype, stratified by age category. TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Some values for adults presented as aggregated estimates due to small cell sizes. Medicaid expenditures (2024 US$) for patients with congenitally diseased pulmonary valve phenotypes, 2006-2019, stratified by cardiac diagnosis Data represent predicted means and 95% CIs, derived from log-linear models from a total of 1068 people (p) over a total of 7594 Medicaid-enrolled person-years (p-yr), adjusted for sex, race/ethnicity, preoperative comorbidity (noncardiac congenital anatomic abnormality, chromosomal abnormality, or syndrome), other preoperative risk factors (preoperative mechanical circulatory support, shock persistent at time of surgery, preoperative mechanical ventilation, renal failure requiring dialysis, neurologic deficit, or other preoperative factor), and pulmonary valve phenotype, stratified by age category. TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Some values for adults presented as aggregated estimates due to small cell sizes. Medicaid-enrolled noncardiac comparators displayed a similar pattern in Medicaid expenditures across time, but with roughly one sixth the absolute spending (∼$500 K per person across the life course). Infants had an annual average expenditure of $12 K per person-year, SD $34 K (median $8 K per person-year; IQR, $5 K-$10 K). Expenditures were again lowest in children aged 1 to 12 years old (mean $3 K per person-year, SD $15 K). In later adulthood (45-65 years), expenditures exceeded those observed in the first year of life (mean $14 K per person-year, SD $43 K; median $3 K per person-year; IQR, $0.8 K-10 K) (Table 5). Discussion Using 14 years of Medicaid claims, we characterize longitudinal health care use and Medicaid expenditures for more than 1000 unique patients from NYS enrolled in Medicaid with primary, congenitally diseased PV phenotypes (totaling >7500 Medicaid-enrolled person-years). These data reveal a skewed, inverse parabolic pattern of health care use and health-related Medicaid expenditures across the life course; inpatient days, emergency department visits, primary care sick visits, outpatient subspecialist visits, and total Medicaid expenditures were all greatest in this first year of life across all diagnostic groups, nadiring in childhood, before increasing again as patients entered adulthood. The total health care burden was 6 times that observed among Medicaid-enrolled noncardiac comparators and was associated with a steep increase in health care use that began in early and middle adulthood. It should be further noted that the large health care use in this population was not driven by a small number of individuals. By the time patients were in their 20s and 30s, we observed a large number of high-resource users, including 8% of young adults seeing primary care doctors for sick visits ≥5 times per year and 23% of young adults admitted to inpatient units each year—with use increasing even more as patients enter their fifth and sixth decades of life. Further, although the incidence of cardiac procedures (and rates of Medicaid reimbursement) was greatest in infancy, as would be expected, 16% of patients per year older than age 45 years of age were estimated to undergo at least 1 cardiac procedure. These data extend our previous work on longitudinal health care use for patients who undergo congenital heart surgical,1 quantifying the significant health care burden experienced by patients with congenitally diseased PV phenotypes in early and middle adulthood and demonstrating the feasibility of leveraging population-level, clinical registry data, linked to Medicaid claims and the National Death Index, to characterize comprehensive, baseline health care use and Medicaid expenditures for specific pediatric populations across the lifespan. As scientists and government agencies balance the desire to bring newer, better therapies to patients and the need for thorough evaluation of safety and efficacy, one thing has become clear: Better, population-level approaches are needed to understand and improve the longitudinal care we provide.9, 10, 11 The Veterans Health Administration (VA) has led the way; leveraging integrated medical records across 172 medical centers and 1138 outpatient clinics and continuous remote monitoring, it created a National Cardiac Device Surveillance Program, facilitating postmarket monitoring implantable cardiac devices for nearly 70,000 veterans.15 In a recent editorial comment regarding the VA's Surveillance Program, the former Commissioner of Food and Drugs for the US Food and Drug Administration lamented the lack of integrated data outside the VA.16 Linking clinical registry and administrative claims data can overcome this hurdle. Our data represent all life-years covered by NYS Medicaid and not a single, continuously enrolled cohort. Therefore, we present event rates per life-year Medicaid-enrolled and total costs to the NYS insurance system. Further, it should be assumed that changes in treatment availability and survival in the current era or in the future will impact future health care use and expenditures for children born today. Future studies will be needed to explore the clinical impacts and cost-effectiveness of these advances. Our data should be interpreted in light of a few additional considerations. First, our cohort was limited to NYS Medicaid enrollees. Extrapolation to other geographies would require not only adjustment for regional price level for medical services but also consideration of differences in Medicaid eligibility, coverage, and payments across geographies and regional differences in baseline health, health care access, and treatments. Further, it is known that low-income populations (ie, Medicaid-eligible populations)—both with and without congenital heart disease—have worse health outcomes than greater-income, privately ensured, populations, although the impacts on health care use and related expenditures are variable and associated with regional and age-related differences in and health insurance and health care access.17, 18, 19, 20 Third, we provide benchmark data from noncardiac comparators, not specifically “healthy children.” This was done because both children with cardiac disease and the broader pediatric population can have other, noncardiac conditions that influence their health care needs, and because the population incidence and severity of many of these conditions is modified by the presence of congenital heart disease. It is possible that the differences in health care use and expenditures between patients with congenital PV disease and comparators with no comorbidities might be greater than the differences we describe. Finally, total “cardiac-related” health care use and Medicaid expenditures are likely greater than our estimates. To ensure accuracy, we restricted our outcomes to those readily measured in claims.12 We measured only visits in which cardiac procedures were billed; we did not include pre- or postprocedure routine visits nor follow-up for complications. Furthermore, we made no attempt to quantify the extent to which cardiac conditions caused or exacerbated comorbid, “noncardiac” conditions—such as neurodevelopmental delays in patients after hypoxia, bypass, or perioperative stroke. In conclusion, this work describes the life-long, high health care burden for patients with primary, congenitally diseased PV phenotypes and demonstrates that population-level, clinical registry data, linked to administrative claims and the National Death Index, can be used to characterize comprehensive, longitudinal, global disease burden for specific pediatric populations. Conflict of Interest Statement The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. Footnotes This work was supported by the National Institutes of Health/National Heart, Lung, and Blood Institute (R01HL150044) and Autus Valve Technologies, Inc. Dr Woo receives salary support from the National Institutes of Health/National Heart, Lung, and Blood Institute (K01HL171819). The views and opinions expressed in this paper are those of the authors and do not necessarily reflect the official policy or position of the National Institutes of Health, or the New York State Department of Health. Examples of analysis performed within this article are only examples. They should not be used in real-world analytic products. Appendix E1 Table E1Inpatient days for patients with congenitally diseased pulmonary valve across the life coursePulmonary valve phenotypesAge at observation on Medicaid(person-years under observation)[birth years]<1 year old(695 p-yr)(2005-2019)1-4 years old(2222 p-yr)(2001-2018)5-12 years old(2609 p-yr)(1978-2014)13-21 years old(1240 p-yr)(1978-2006)22-44 years old(720 p-yr)(1964-1997)45-65 years old(108 p-yr)(1949-1976)TOF-PS, including VSD-PSPredicted mean(95% CI)33.8(29.9-37.8)3.4(2.6-4.1)0.7(0.5-0.9)1.3(1.0-1.6)3.4(2.3-4.5)6.1(2.1-10.1)TOF-PA, including VSD-PAPredicted mean(95% CI)53.3(43.6-63.1)5.3(3.9-6.7)1.1(0.8-1.5)2.1(1.4-2.7)5.4(3.5-7.4)∗AVSD-TOFPredicted mean(95% CI)49.0(37.2-60.7)4.9(3.4-6.4)1.0(0.7-1.4)1.9(1.3-2.5)5.0(3.2-6.8)∗TOF Absent PVPredicted mean(95% CI)66.3(42.3-90.3)6.6(3.7-9.5)1.4(0.8-2.0)2.6(1.5-3.6)6.7(3.5-10.0)∗Valvar PS no VSDPredicted mean(95% CI)32.5(23.8-41.3)3.2(2.1-4.3)0.7(0.4-0.9)1.3(0.8-1.7)3.3(2.0-4.6)∗OtherPredicted mean(95% CI)43.3(28.3-58.3)4.3(2.7-6.0)0.9(0.6-1.3)1.7(1.0-2.3)4.4(2.8-6.0)∗Pulmonary valve patient data derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis.∗Values suppressed because of small sample size. Inpatient days for patients with congenitally diseased pulmonary valve across the life course Pulmonary valve patient data derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Values suppressed because of small sample size. Table E2Emergency department visits for patients with congenitally diseased pulmonary valve phenotypes across the life coursePulmonary valve phenotypesAge at observation on Medicaid(person-years under observation)(birth years)<1 year old(695 p-yr)(2005-2019)1-4 years old(2222 p-yr)(2001-2018)5-12 years old(2609 p-yr)(1978-2014)13-21 years old(1240 p-yr)(1978-2006)22-44 years old(720 p-yr)(1964-1997)45-65 years old(108 p-yr)(1949-1976)TOF-PS, including VSD-PSPredicted mean(95% CI)0.9(0.7-1.0)0.6(0.6-0.7)0.3(0.3-0.4)0.3(0.3-0.4)0.4(0.3-0.5)0.4(0.2-0.7)TOF-PA, including VSD-PAPredicted mean(95% CI)0.9(0.6-1.2)0.6(0.4-0.7)0.4(0.3-0.5)1.0(0.5-1.4)0.4(0.2-0.7)∗AVSD-TOFPredicted mean(95% CI)1.0(0.5-1.6)0.6(0.4-0.8)0.4(0.2-0.5)0.2(0.1-0.2)0.3(0.0-0.7)∗TOF absent PVPredicted mean(95% CI)0.7(0.0-1.4)0.8(0.2-1.3)0.2(0.1-0.2)0.2(0.0-0.4)0.3(0.0-0.7)∗Valvar PS no VSDPredicted mean(95% CI)0.9(0.4-1.3)0.6(0.4-0.8)0.2(0.1-0.3)0.2(0.0-0.4)0.9(0.3-1.5)∗OtherPredicted mean(95% CI)0.8(0.1-1.6)0.6(0.3-0.9)0.3(0.2-0.4)0.4(0.1-0.6)0.9(0.3-1.4)∗Pulmonary valve patient data derived from a total of 1068 people (p) over 7,594 Medicaid-enrolled person-years (p-yr). Emergency department visits derived from predicted mean and 95% CIs derived from diagnosis specific models. TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis.∗Values suppressed due to small sample size. Emergency department visits for patients with congenitally diseased pulmonary valve phenotypes across the life course Pulmonary valve patient data derived from a total of 1068 people (p) over 7,594 Medicaid-enrolled person-years (p-yr). Emergency department visits derived from predicted mean and 95% CIs derived from diagnosis specific models. TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Values suppressed due to small sample size. Table E3Primary care sick-visits for patients with congenitally diseased pulmonary valve phenotypes across the life coursePulmonary valve phenotypesAge at observation on Medicaid(person-years under observation)(birth years)<1 year old(695 p-yr)(2005-2019)1-4 years old(2222 p-yr)(2001-2018)5-12 years old(2609 p-yr)(1978-2014)13-21 years old(1240 p-yr)(1978-2006)22-44 years old(720 p-yr)(1964-1997)45-65 years old(108 p-yr)(1949-1976)TOF-PS, including VSD-PSPredicted mean(95% CI)12.3(11.6-13.1)6.4(6.0-6.7)3.5(3.4-3.7)2.5(2.3-2.7)2.9(2.6-3.2)3.7(2.9-4.4)TOF-PA, including VSD-PAPredicted mean(95% CI)14.0(12.3-15.6)7.2(6.4-8.0)4.0(3.6-4.5)2.8(2.5-3.2)3.3(2.8-3.7)∗AVSD-TOFPredicted mean(95% CI)14.1(12.5-15.8)7.3(6.5-8.1)4.1(3.6-4.5)2.9(2.5-3.2)3.3(2.8-3.8)∗TOF Absent PVPredicted mean(95% CI)15.8(13.6-18.1)8.2(7.1-9.3)4.6(3.9-5.2)3.2(2.8-3.7)3.7(3.1-4.3)∗Valvar PS no VSDPredicted mean(95% CI)13.6(10.0-17.3)7.0(5.0-9.1)3.9(2.8-5.0)2.8(2.0-3.5)3.2(2.3-4.1)∗OtherPredicted mean(95% CI)13.9(12.1-15.6)7.2(6.3-8.0)4.0(3.5-4.5)2.8(2.5-3.2)3.3(2.7-3.8)∗Pulmonary valve patient data derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis.∗Values suppressed due to small sample size. Primary care sick-visits for patients with congenitally diseased pulmonary valve phenotypes across the life course Pulmonary valve patient data derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Values suppressed due to small sample size. Table E4Subspecialist visits for patients with congenitally diseased pulmonary valve phenotypes across the life coursePulmonary valve phenotypesAge at observation on Medicaid(person-years under observation)(birth years)<1 year old(695 p-yr)(2005-2019)1-4 years old(2222 p-yr)(2001-2018)5-12 years old(2609 p-yr)(1978-2014)13-21 years old(1240 p-yr)(1978-2006)22-44 years old(720 p-yr)(1964-1997)45-65 years old(108 p-yr)(1949-1976)TOF-PS, including VSD-PSPredicted mean(95% CI)6.4(6.0-6.9)2.5(2.3-2.6)1.6(1.5-1.7)1.7(1.5-1.9)2.7(2.4-3.0)4.6(3.4-5.8)TOF-PA, including VSD-PAPredicted mean(95% CI)9.0(8.0-10.1)3.4(3.1-3.8)2.2(2.0-2.5)2.4(2.0-2.7)3.8(3.3-4.4)∗AVSD-TOFPredicted mean(95% CI)7.1(6.1-8.1)2.7(2.3-3.1)1.8(1.5-2.0)1.9(1.6-2.2)3.0(2.5-3.5)∗TOF Absent PVPredicted mean(95% CI)6.6(5.4-7.9)2.5(2.1-3.0)1.6(1.3-1.9)1.7(1.4-2.1)2.8(2.2-3.4)∗Valvar PS no VSDPredicted mean(95% CI)7.5(6.2-8.8)2.9(2.4-3.3)1.9(1.5-2.2)2.0(1.6-2.3)3.2(2.6-3.7)∗OtherPredicted mean(95% CI)7.6(6.3-8.9)2.9(2.4-3.4)1.9(1.6-2.2)2.0(1.6-2.4)3.2(2.7-3.7)∗Pulmonary valve patient data derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis.∗Values suppressed due to small sample size. Subspecialist visits for patients with congenitally diseased pulmonary valve phenotypes across the life course Pulmonary valve patient data derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Values suppressed due to small sample size. Table E5Ambulatory procedure visits for patients with congenitally diseased pulmonary valve phenotypes across the life coursePulmonary valve phenotypesAge at observation on Medicaid(person-years under observation)(birth years)<1 year old(695 p-yr)(2005-2019)1-4 years old(2222 p-yr)(2001-2018)5-12 years old(2609 p-yr)(1978-2014)13-21 years old(1240 p-yr)(1978-2006)22-44 years old(720 p-yr)(1964-1997)45-65 years old(108 p-yr)(1949-1976)TOF-PS, including VSD-PSPredicted mean(95% CI)0.9(0.8-1.1)0.5(0.4-0.5)0.3(0.3-0.4)0.4(0.3-0.5)0.7(0.4-0.9)0.4(0.2-0.7)TOF-PA, including VSD-PAPredicted mean(95% CI)1.4(1.1-1.7)0.7(0.5-0.9)0.5(0.5-0.9)0.6(0.4-0.7)1.0(0.6-1.4)∗AVSD-TOFPredicted mean(95% CI)1.2(0.9-1.6)0.6(0.4-0.8)0.4(0.3-0.5)0.5(0.3-0.6)0.9(0.5-1.3)∗TOF absent PVPredicted mean(95% CI)0.8(0.5-1.1)0.4(0.2-0.6)0.3(0.2-0.4)0.3(0.2-0.5)0.6(0.2-0.9)∗Valvar PS no VSDPredicted mean(95% CI)1.6(0.9-2.2)0.8(0.4-1.1)0.5(0.3-0.7)0.6(0.3-0.9)1.1(0.5-1.7)∗OtherPredicted mean(95% CI)1.8(0.7-2.0)0.9(0.3-1.5)0.6(0.2-1.0)0.7(0.3-1.1)1.3(0.2-2.4)∗Pulmonary valve patient data derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). Ambulatory procedure visits are defined using the Centers for Disease Control and Prevention’s payment classification for “ambulatory surgical services,” which includes all surgical and catheterization procedures performed in ambulatory surgical or hospital-based centers for which the expected length-of-stay is <24 hours. TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis.∗Values suppressed due to small sample size. Ambulatory procedure visits for patients with congenitally diseased pulmonary valve phenotypes across the life course Pulmonary valve patient data derived from a total of 1068 people (p) over 7594 Medicaid-enrolled person-years (p-yr). Ambulatory procedure visits are defined using the Centers for Disease Control and Prevention’s payment classification for “ambulatory surgical services,” which includes all surgical and catheterization procedures performed in ambulatory surgical or hospital-based centers for which the expected length-of-stay is <24 hours. TOF-PS, including VSD-PS, Tetralogy of Fallot with pulmonary stenosis, including ventricular septal defect with pulmonary stenosis; TOF-PA, including VSD-PA, tetralogy of Fallot with pulmonary atresia, including ventricular septal defect with pulmonary atresia; AVSD-TOF, atrioventricular septal defect with TOF; TOF Absent PV, TOF with absent pulmonary valve; Valvar PS no VSD, valvar pulmonary stenosis without VSD; Other, patients with documented primary congenital pulmonary valve disease, but for whom the combination of diagnostic and procedure codes in the Society of Thoracic Surgeons Congenital Heart Surgery Database data left ambiguity regarding the specific, underlying clinical diagnosis. Values suppressed due to small sample size. References